Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-31.44 Insider Own94.73% Shs Outstand1.82M Perf Week0.00%
Market Cap289.96M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.67M Perf Month3.51%
Income-57.21M PEG- EPS next Q- Inst Own2.51% Short Float0.80% Perf Quarter4.57%
Sales0.35M P/S828.47 EPS this Y- Inst Trans-73.13% Short Ratio1.77 Perf Half Y21.84%
Book/sh1.79 P/B5.12 EPS next Y- ROA-53.08% Short Interest0.01M Perf Year20.86%
Cash/sh2.22 P/C4.12 EPS next 5Y47.30% ROE-68.60% 52W Range4.35 - 9.60 Perf YTD22.82%
Dividend Est.- P/FCF- EPS past 5Y-41.57% ROI-78.35% 52W High-4.69% Beta1.69
Dividend TTM- Quick Ratio7.51 Sales past 5Y10.54% Gross Margin-1049.71% 52W Low110.34% ATR (14)0.32
Dividend Ex-Date- Current Ratio7.51 EPS Y/Y TTM42.76% Oper. Margin-16553.16% RSI (14)52.62 Volatility2.58% 3.02%
Employees99 Debt/Eq0.34 Sales Y/Y TTM-76.42% Profit Margin-16439.94% Recom5.00 Target Price5.00
Option/ShortNo / Yes LT Debt/Eq0.29 EPS Q/Q28.27% Payout- Rel Volume0.56 Prev Close9.00
Sales Surprise33.33% EPS Surprise-16.89% Sales Q/Q-46.72% Earnings- Avg Volume7.55K Price9.15
SMA201.03% SMA502.78% SMA20020.56% Trades Volume4,245 Change1.67%
Date Action Analyst Rating Change Price Target Change
Jan-07-22Downgrade BofA Securities Neutral → Underperform $3
Sep-27-21Downgrade JP Morgan Neutral → Underweight $10 → $7
Aug-31-21Downgrade BTIG Research Buy → Neutral
Aug-12-21Downgrade Piper Sandler Overweight → Neutral $13 → $9
Aug-11-21Downgrade JP Morgan Overweight → Neutral $17 → $10
Mar-09-21Initiated Piper Sandler Overweight $17
Mar-09-21Initiated JP Morgan Overweight $18
Mar-09-21Initiated BTIG Research Buy $18
Mar-09-21Initiated BofA Securities Neutral $14
May-08-24 01:53PM
Apr-27-24 06:00AM
Mar-28-24 11:54PM
Nov-14-23 08:27AM
08:00AM Loading…
Aug-10-23 04:45PM
Aug-03-23 08:00AM
Aug-02-23 08:00AM
Jul-27-23 08:00AM
Jul-24-23 08:00AM
Jul-05-23 08:00AM
May-23-23 08:00AM
May-11-23 05:22PM
04:05PM Loading…
May-04-23 08:00AM
Mar-22-23 04:05PM
Nov-09-22 06:13AM
Nov-03-22 04:05PM
Aug-08-22 10:48AM
Aug-03-22 07:50AM
Aug-02-22 04:05PM
May-10-22 04:05PM
Apr-26-22 08:00AM
Apr-25-22 12:08PM
Apr-06-22 06:11PM
Mar-15-22 09:30PM
08:00AM Loading…
Mar-01-22 08:00AM
Feb-23-22 04:23AM
Feb-01-22 10:05AM
Dec-25-21 02:38AM
Dec-21-21 02:00PM
Dec-20-21 04:00PM
Dec-14-21 11:16AM
Dec-13-21 11:30PM
Dec-10-21 09:00AM
Dec-09-21 06:16PM
Dec-08-21 07:30PM
Dec-03-21 03:15PM
Dec-02-21 06:53PM
Nov-16-21 06:00AM
Nov-15-21 04:05PM
Nov-12-21 12:00PM
Nov-11-21 04:00PM
Nov-08-21 08:00AM
Oct-26-21 08:00AM
Oct-12-21 12:36PM
Sep-14-21 04:00PM
Sep-13-21 07:00PM
Sep-09-21 06:00PM
Sep-03-21 08:49AM
Aug-31-21 08:25PM
Aug-30-21 04:30PM
Aug-11-21 02:10PM
Aug-10-21 04:05PM
Jul-27-21 08:00AM
May-12-21 08:00AM
May-11-21 04:05PM
May-04-21 08:00AM
Apr-28-21 08:00AM
Mar-18-21 08:00AM
Mar-09-21 10:07AM
Mar-08-21 08:00AM
Feb-17-21 04:05PM
Feb-12-21 05:05PM
Feb-11-21 11:39PM
Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Chicago, IL.